title: [New oral anticoagulants: better than vitamin K antagonists?].
abstract: Many years of practical use and intensive scientific research have allowed vitamin K antagonists to become a cornerstone of treatment of internal diseases. Nevertheless, limitations in pharmacokinetics and -dynamics of vitamin K antagonists and the availability of new drugs in regard to a targeted anticoagulation therapy ask for a new review of the situation. Proof of effectiveness for the perioperative prophylaxis of venous thrombosis after hip and knee replacement has already been achieved for the direct thrombin inhibitor dabigatran etexilate as well as for the factor Xa inhibitors rivaroxaban und apixaban compared to low molecular weight heparins. These new drugs are now also investigated in patients with internal diseases. For the long-term application (6 or 12 months) concerning the treatment of venous thrombosis and/or stroke prophylaxis in patients with atrial fibrillation data is already available for the direct thrombin inhibitor dabigatran etexilate. Depending on its dosage its effectiveness in comparison with vitamin K antagonists is equal or even better without disadvantages in safety. However, vitamin K antagonists will remain the standard oral anticoagulation until open questions regarding e.g. insufficient therapy adherence (with termination rates up to 20%) or problems with drug interactions of the new competitive products have been completely answered.
authors.affiliation: FESC, Klinik am See, Rehabilitationszentrum für Innere Medizin, Seebad 84, Rüdersdorf, Germany. heinz.voeller@klinikamsee.com
authors.forename: H
authors.initials: H
authors.lastname: Völler
authors.forename: S
authors.initials: S
authors.lastname: Alban
authors.forename: D
authors.initials: D
authors.lastname: Westermann
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D058833:Antithrombin Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D058833:Antithrombin Proteins; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran
references.citation: Circulation. 2010 Apr 6;121(13):1523-32
references.pmid: 20368532
references.citation: Stroke. 2009 Apr;40(4):1410-6
references.pmid: 19182090
references.citation: N Engl J Med. 2008 Jun 26;358(26):2827-9
references.pmid: 18579818
references.citation: Stroke. 2009 Jan;40(1):235-40
references.pmid: 18757287
references.citation: Curr Pharm Des. 2008;14(12):1152-75
references.pmid: 18473863
references.citation: Thromb Haemost. 2010 Apr;103(4):833-40
references.pmid: 20135077
references.citation: Thromb Haemost. 2010 Jul;104(1):49-60
references.pmid: 20539909
references.citation: Hamostaseologie. 2005 Feb;25(1):39-49
references.pmid: 15711719
references.citation: Hamostaseologie. 2007 Sep;27(4):282-9
references.pmid: 17938768
references.citation: Am Heart J. 2010 Mar;159(3):340-347.e1
references.pmid: 20211293
references.citation: Eur Heart J. 2004 Aug;25(16):1385-94
references.pmid: 15302102
references.citation: Drug Metab Dispos. 2009 Jan;37(1):74-81
references.pmid: 18832478
references.citation: Chest. 2008 Jun;133(6 Suppl):381S-453S
references.pmid: 18574271
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: N Engl J Med. 2009 Dec 10;361(24):2342-52
references.pmid: 19966341
references.citation: Chest. 2008 Jun;133(6 Suppl):299S-339S
references.pmid: 18574269
references.citation: Am Heart J. 2010 Mar;159(3):331-9
references.pmid: 20211292
references.citation: Expert Opin Investig Drugs. 2008 Dec;17(12):1937-45
references.pmid: 19012508
references.citation: Ann Intern Med. 2007 Jun 19;146(12):857-67
references.pmid: 17577005
references.citation: Lancet. 2006 Feb 4;367(9508):404-11
references.pmid: 16458764
references.citation: Eur Heart J. 2004 Aug;25(16):1395-404
references.pmid: 15321697
references.citation: J Am Coll Cardiol. 2007 Nov 27;50(22):2156-61
references.pmid: 18036454
references.citation: Stroke. 2001 Feb;32(2):392-8
references.pmid: 11157172
references.citation: Europace. 2009 Apr;11(4):423-34
references.pmid: 19153087
references.citation: Eur Heart J. 2009 Dec;30(24):2969-77c
references.pmid: 19535417
references.citation: Lancet. 2010 Mar 6;375(9717):807-15
references.pmid: 20206776
references.citation: Eur Heart J. 2005 Nov;26(22):2422-34
references.pmid: 16204266
references.citation: Eur Heart J. 2006 Aug;27(16):1979-2030
references.pmid: 16885201
references.citation: Thromb Haemost. 2010 Feb;103(2):360-71
references.pmid: 20024501
references.citation: Drug Metab Dispos. 2010 Mar;38(3):448-58
references.pmid: 19940026
references.citation: Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):41-8
references.pmid: 16254201
references.citation: Thromb Haemost. 2010 Jan;103(1):34-9
references.pmid: 20062925